

Phytochemical Constituents of the Leaves of *Hosta longipes*[†]

Chung Sub Kim, Ki Hyun Kim, and Kang Ro Lee*

Natural Products Laboratory, School of Pharmacy, Sungkyunkwan University, Suwon 440-746, Korea

Abstract – Phytochemical investigation of the 80% MeOH extract from the leaves of *Hosta longipes* resulted in the isolation of sixteen compounds (**1** - **16**). The structures of the compounds were elucidated by spectroscopic methods to be methyl 10,10-dimethoxydecanoate (**1**), methyl 10-hydroxy-8*E*,12*Z*-octadecadienoate (**2**), methyl coriolate (**3**), *trans*-phytol (**4**), phytene-1,2-diol (**5**), phyton (**6**), (3*S*,5*R*,6*S*,7*E*,9*R*)-7-megastigmen-3,6,9-triol (**7**), (3*S*,5*R*,6*S*,9*R*)-3,6,9-trihydroxymegastigman-7-ene (**8**), shikimic acid (**9**), *p*-coumaramide (**10**), *trans-N-p*-coumaroyltyramine (**11**), *cis-N*-coumaroyltyramine (**12**), tryptophan (**13**), thymidine (**14**), adenosine (**15**), and deoxyadenosine (**16**). Compound **1** was synthesized, but not yet isolated from natural source, and compounds **2** - **16** were isolated for the first time from this plant source.

Keywords – *Hosta longipes*, Liliaceae, fatty acid, phenolic compound

Introduction

Hosta longipes (Fr. et Sav.) Matsumura (Liliaceae), widely distributed throughout Korea, China, and Japan, is an edible vegetable in Korea. It has long been used as a traditional Korean medicine for treating cough, sputum, laryngopharyngitis, burns, swelling, snake bites and inflammation.^{1,2} Previous phytochemical investigations of this plant led to the isolation of steroidal saponins.^{3,4} In the course of our continuing search for biologically active components from Korean medicinal plants, we investigated the constituents of the leaves of *H. longipes* and reported the isolation of steroidal saponins and flavonoids and their anti-inflammatory effects.^{5,6} In our continuing study on this source, we further isolated sixteen compounds (**1** - **16**). Their structures were elucidated by physicochemical and spectroscopic methods. Compound **1** was isolated for the first time from nature and compounds **2** - **16** were isolated for the first time from this plant source.

Experimental

General experimental procedures – Optical rotations were measured on a Jasco P-1020 polarimeter in MeOH. IR spectra were recorded on a Bruker IFS-66/S FT-IR

spectrometer. HRFABMS were obtained on a JEOL JMS700 mass spectrometer. NMR spectra were recorded on a Varian UNITY INOVA 500 NMR spectrometer operating at 500 MHz (¹H) and 125 MHz (¹³C) with chemical shifts given in ppm (δ). Preparative HPLC was conducted using a Gilson 306 pump with Shodex refractive index detector and Apollo Silica 5 μ column (250 × 22 mm i.d.). Silica gel 60 (Merck, 70 - 230 mesh and 230 - 400 mesh) was used for column chromatography. The packing material for molecular sieve column chromatography was Sephadex LH-20 (Pharmacia Co.). TLC was performed using Merck precoated silica gel F₂₅₄ plates. Spots were detected on TLC under UV light or by heating after spraying with 10% H₂SO₄ in C₂H₅OH (v/v).

Plant materials – Leaves of *H. longipes* were collected in Taebaek City, Korea, in June 2010. The plant was identified by one of the authors (K. R. Lee). A voucher specimen (SKKU-NPL 1103) of the plant has been deposited at the herbarium of the School of Pharmacy, Sungkyunkwan University, Suwon, Korea.

Extraction and isolation – Leaves of *H. longipes* (2.5 kg) were extracted with 80% MeOH at room temperature and filtered. The filtrate was evaporated under reduced pressure to give a MeOH extract (190 g), which was suspended in water (800 mL) and solvent-partitioned to give *n*-hexane (3 g), CHCl₃ (14 g), EtOAc (3 g), and *n*-BuOH (24 g) layers. The *n*-hexane (3 g) layer was separated over a silica gel column (*n*-hexane: EtOAc = 7 : 1 – 1 : 1) to yield nine fractions (H1 – H9). Fraction H2 (370 mg) was chromatographed on an RP-C₁₈ silica

[†]Dedicated to Prof. Okpyo Zee of the Sungkyunkwan University for his leading works on Natural Products Research.

*Author for correspondence

Kang Ro Lee, Natural Products Laboratory, School of Pharmacy, Sungkyunkwan University, Suwon 440-746, Korea
Tel: +82-31-290-7710; E-mail: krlee@skku.edu

gel column (90% MeOH) to give three subfractions (H21 – H23). Subfraction H21 (100 mg) was purified over a silica gel semi-prep. HPLC (hexane : CHCl₃ : EtOAc = 9 : 2 : 1) to afford compounds **2** (10 mg, *Rt* = 13.1 min) and **3** (3 mg, *Rt* = 16.0 min). Subfraction H22 (20 mg) was purified by an RP-C₁₈ semi-prep. HPLC (95% MeCN) to afford compound **4** (8 mg, *Rt* = 18.7 min). Fraction H7 (150 mg) was purified with an RP-C₁₈ silica Lobar A[®]-column (80% MeOH) and silica gel semi-prep. HPLC (hexane : EtOAc = 3 : 1) to afford compound **5** (6 mg, *Rt* = 11.0 min). The CHCl₃ (14 g) layer was separated over a silica gel column (*n*-hexane : EtOAc = 7 : 1 – 1 : 1) to yield seven fractions (C1 – C7). Fraction C1 (1.0 g) was separated over an RP-C₁₈ silica gel column (90% MeOH) and purified by a silica gel semi-prep. HPLC (hexane : EtOAc = 2 : 1) to afford compound **1** (11 mg, *Rt* = 13.4 min). Fraction C2 (200 mg) was purified with an RP-C₁₈ silica Lobar A[®]-column (90% MeOH) and silica gel semi-prep. HPLC (hexane : EtOAc = 7 : 1) to afford compound **6** (4 mg, *Rt* = 17.0 min). The EtOAc (3 g) layer was chromatographed over a Sephadex LH-20 column (90% MeOH) to yield nine fractions (E1 – E9). Fraction E2 (800 mg) separated over a silica gel column (CHCl₃ : MeOH = 12 : 1) and further purified with RP-C₁₈ semi-prep. HPLC (50% MeOH) to afford compounds **7** (2 mg, *Rt* = 11.8 min) and **8** (3 mg, *Rt* = 12.9 min). Fraction E3 (700 mg) was separated over an RP-C₁₈ silica gel column (90% MeOH) to give six subfractions (E31 – E36). Subfraction E31 (200 mg) was purified with an RP-C₁₈ silica Lobar A[®]-column (80% MeOH) and silica gel semi-prep. HPLC (CHCl₃ : MeOH = 2 : 1) to afford compounds **9** (7 mg, *Rt* = 16.7 min), **14** (6 mg, *Rt* = 18.7 min), **15** (3 mg, *Rt* = 20.3 min), and **16** (3 mg, *Rt* = 25.3 min). Subfraction E33 (80 mg) was purified by an RP-C₁₈ semi-prep. HPLC (30% MeCN) to afford compounds **11** (3 mg, *Rt* = 11.8 min) and **12** (3 mg, *Rt* = 10.4 min). Compound **10** (3 mg) was obtained by purification of subfraction E4 (210 mg) using a silica gel semi-prep. HPLC (CHCl₃ : MeOH : H₂O = 9 : 2 : 0.2). Fraction E9 (100 mg) was purified with a silica gel semi-prep. HPLC (CHCl₃ : MeOH : H₂O = 2 : 1 : 0.2) to yield compound **13** (7 mg, *Rt* = 15.0 min).

Methyl 10,10-dimethoxydecanoate (1) – Colorless gum. IR (KBr) ν_{\max} cm⁻¹: 2951 (C-H), 1723 (C=O), 1284, 1032; ¹H and ¹³C NMR: see Table 1; HRFABMS *m/z* 269.1733 [M + Na]⁺; (calcd for C₁₃H₂₆O₄ Na, 269.1729).

Methyl 10-hydroxy-8E,12Z-octadecadienoate (2) – Colorless gum. [α]_D²⁵: -3.0 (*c* 0.25, CHCl₃); ¹H NMR (CDCl₃, 500 MHz): δ 5.67 (1H, dt, *J* = 15.5, 6.5 Hz, H-12), 5.54 (1H, m, H-9), 5.48 (1H, m, H-13), 5.37 (1H, m,

Table 1. ¹H (500 MHz) and ¹³C NMR (125 MHz) data of **1** in CDCl₃

Position	1	
	δ_{H} (<i>J</i> in Hz)	δ_{C}^a
1		174.5
2	2.29, t (7.5)	34.3
3	1.59, m	24.7
4	1.30 – 1.34, m	29.4
5	1.30 – 1.34, m	29.1
6	1.30 – 1.34, m	29.2
7	1.30 – 1.34, m	29.5
8	1.30 – 1.34, m	25.1
9	1.61, m	32.7
10	4.34, t (5.5)	104.8
1-OCH ₃	3.66, s	51.6
10-OCH ₃	3.30, s	52.8

^aThe assignments were based on HMQC and HMBC experiments.

H-8), 4.08 (1H, m, H-10), 3.67 (3H, s, OCH₃), 2.30 (2H, t, *J* = 7.5 Hz, H-2), 2.25 (2H, m, H-11), 2.04 (4H, m, H-7 and 14), 1.62 (2H, m, H-17), 1.31 – 1.40 (12H, m, H-3 to H-6, H-15, H-16), 0.90 (3H, t, *J* = 7.0 Hz, H-18); ¹³C NMR (CDCl₃, 125 MHz): δ 174.5 (C-1), 133.4 (C-8), 132.5 (C-9), 132.4 (C-13), 125.0 (C-12), 72.7 (C-10), 51.6 (OCH₃), 35.7 (C-11), 34.3 (C-7), 32.1 (C-2), 31.5 (C-16), 29.8 (C-4), 29.3 (C-5, C-6, C-15), 27.6 (C-14), 25.2 (C-3), 22.4 (C-17), 14.1 (C-18). FABMS *m/z*: 311.3 [M + H]⁺.

Methyl coriolate (3) – Colorless gum. [α]_D²⁵: +10.2 (*c* 0.30, CHCl₃); ¹H NMR (CDCl₃, 500 MHz): δ 6.49 (1H, dd, *J* = 15.0, 10.5 Hz, H-11), 5.97 (1H, t, *J* = 10.5 Hz, H-10), 5.66 (1H, dd, *J* = 15.0, 7.0 Hz, H-12), 5.45 (1H, dt, *J* = 10.5, 8.0 Hz, H-9), 4.16 (1H, q, *J* = 7.0, H-13), 3.67 (3H, s, H-OCH₃), 2.30 (2H, t, *J* = 7.5 Hz, H-2), 2.18 (2H, m, H-8), 1.26 – 1.62 (18H, m, H-3 to H-7, H-14 to H-17), 0.89 (3H, t, *J* = 7.5 Hz, H-18). FABMS *m/z*: 311.3 [M + H]⁺.

trans-Phytol (4) – Colorless oil. ¹H NMR (500 MHz, CD₃OD): δ 5.35 (1H, t, *J* = 7.0 Hz, H-2), 4.07 (2H, d, *J* = 6.5 Hz, H-1), 2.00 (2H, t, *J* = 6.5 Hz, H-4), 1.65 (3H, s, H-20), 1.52 – 1.05 (19H, m), 0.87 (9H, d, *J* = 6.5 Hz, H-16, 18, 19), 0.88 (3H, d, *J* = 6.5 Hz, H-17); ¹³C NMR (125 MHz, CD₃OD): δ 138.4 (C-3), 123.6 (C-2), 58.2 (C-1), 39.8 (C-4), 39.4 (C-14), 37.4 (C-8), 37.3 (C-10), 37.2 (C-12), 36.6 (C-6), 32.8 (C-7), 32.7 (C-11), 27.9 (C-15), 25.1 (C-5), 24.7 (C-13), 24.3 (C-9), 22.0 (C-17), 21.9 (C-16), 19.1 (C-19), 19.0 (C-18), 15.0 (C-20). FABMS *m/z*: 319.3 [M + Na]⁺

Phytene-1,2-diol (5) – Colorless gum. ¹H NMR (500




Fig. 1. The structures of 1 - 16 isolated from *H. longipes*.

MHz, CD₃OD): δ 5.07 (1H, s, H-20a), 4.89 (1H, s, H-20b), 4.07 (1H, dd, $J=7.0, 3.5$ Hz, H-2), 3.58 (1H, dd, $J=6.5, 4.0$ Hz, H-1a), 3.44 (1H, dd, $J=6.5, 2.5$ Hz, H-1b), 2.09 - 1.97 (2H, m, H-4), 1.57 - 1.06 (19H, m), 0.88 (9H, d, $J=7.0$ Hz, H-16, 18, 20), 0.86 (3H, d, $J=7.0$ Hz, H-19); ¹³C NMR (125 MHz, CD₃OD): δ 149.6 (C-3), 109.6 (C-17), 75.4 (C-2), 65.3 (C-1), 39.3 (C-14), 37.3 (C-8), 37.2 (C-10, 12), 36.8 (C-6), 32.7 (C-4), 32.5 (C-7, 11), 27.9 (C-15), 25.5 (C-5), 24.6 (C-13), 24.3 (C-9), 21.9 (C-20), 21.8 (C-16), 19.0 (C-19), 18.9 (C-18). EIMS m/z : 312.3 [M]⁺.

Phyton (6) – Colorless gum. $[\alpha]_D^{25}$: +2.1 (c 0.15, CHCl₃); ¹H NMR (500 MHz, CDCl₃): δ 2.40 (2H, t, $J=7.5$ Hz, H-3), 2.12 (3H, s, H-1), 1.03 - 1.58 (17H, m, H-4 to H-14), 0.85 (12H, d, $J=7.0$ Hz, H-15 to H-18); ¹³C NMR (125 MHz, CDCl₃): 209.5 (C-2), 44.4 (C-3), 39.6 (C-13), 37.6, 37.5, 37.5 and 36.7 (C-5, C-7, C-9, C-11) 33.0 and 32.9 (C-6, C-10), 30.0 (C-1), 28.2 (C-4), 25.0 (C-14), 24.6 (C-12), 22.9 (C-8), 22.8 and 21.7 (C-15, C-18), 20.0 and 19.8 (C-16, C-17). FABMS m/z : 269.3 [M + H]⁺.

(3S,5R,6S,7E,9R)-7-Megastigmene-3,6,9-triol (7) – Amorphous powder. $[\alpha]_D^{25}$: -11.9 (c 0.15, CH₃OH); ¹H NMR (500 MHz, CD₃OD): δ 5.72 (1H, dd, $J=16.0, 6.0$ Hz, H-8), 5.55 (1H, dd, $J=16.0, 1.0$ Hz, H-7), 4.29 (1H, m, H-9), 3.80 (1H, m, H-3), 1.93 (1H, m, H-5), 1.67 (1H, m, H-4a), 1.66 (1H, m, H-2a), 1.40 (1H, m, H-2b), 1.39 (1H, m, H-4b), 1.24 (3H, d, $J=6.0$ Hz, H-10), 0.98 (3H, s, H-11), 0.89 (3H, s, H-12), 0.81 (3H, d, $J=6.0$ Hz, H-




Fig. 2. Key HMBC (→) and ¹H-¹H COSY (—) correlations of 1.

13); ¹³C NMR (125 MHz, CD₃OD): δ 135.7 (C-8), 134.0 (C-7), 78.3 (C-6), 69.4 (C-9), 67.6 (C-3), 46.1 (C-2), 40.6 (C-1), 40.1 (C-4), 35.6 (C-5), 25.9 (C-11), 25.3 (C-12), 24.3 (C-10), 16.6 (C-13). FABMS m/z : 229.2 [M + H]⁺.

(3S,5R,6S,9R)-3,6,9-Trihydroxymegastigman-7-ene (8) – Amorphous powder. $[\alpha]_D^{25}$: -15.9 (c 0.20, CH₃OH). ¹H-NMR (500 MHz, CD₃OD): 5.73 (1H, dd, $J=16.0, 6.0$ Hz, H-8), 5.55 (1H, dd, $J=16.0, 1.0$ Hz, H-7), 4.29 (1H, m, H-9), 3.80 (1H, m, H-3), 1.94 (1H, m, H-5), 1.68 (1H, m, H-4a), 1.66 (1H, t, $J=12.0$ Hz, H-2a), 1.40 (1H, ddd, $J=12.0, 4.0, 2.0$ Hz, H-2b), 1.39 (1H, q, $J=12.0$ Hz, H-4b), 1.24 (3H, d, $J=6.0$ Hz, H-10), 0.96 (3H, s, H-11), 0.86 (3H, s, H-12), 0.84 (3H, d, $J=7.0$ Hz, H-13); ¹³C-NMR (125 MHz, CD₃OD): δ 135.6 (C-8), 133.9 (C-7), 78.1 (C-6), 69.3 (C-9), 67.5 (C-3), 40.5 (C-1), 40.0 (C-4), 35.5 (C-5), 25.9 (C-12), 25.2 (C-11), 24.2 (C-10), 16.5 (C-13). FABMS m/z : 229.2 [M + H]⁺.

Shikimic acid (9) – Amorphous powder. $[\alpha]_D^{25}$: -12.1 (c 0.20, CH₃OH). ¹H-NMR (500 MHz, CD₃OD): δ 6.48 (1H, m, H-6), 4.28 (1H, t, $J=4.0$ Hz, H-5), 3.90 (1H, m, H-4), 3.53 (1H, m, H-3), 2.81 (1H, dd, $J=18.0, 5.5$ Hz, H-2a), 2.16 (1H, dd, $J=18.0, 4.0$ Hz, H-2b); ¹³C-NMR (125 MHz, CD₃OD): δ 174.2 (C-7), 136.7 (C-1), 130.4

(C-6), 73.2 (C-5), 67.4 (C-4), 66.8 (C-3), 33.4 (C-2). FABMS m/z : 175.1 $[M + H]^+$.

***p*-Coumaramide (10)** – Amorphous powder. $^1\text{H-NMR}$ (500 MHz, CD_3OD): δ 7.35 (2H, d, $J = 8.0$ Hz, H-2, H-6), 7.32 (1H, d, $J = 16.0$ Hz, H-7), 6.75 (2H, d, $J = 8.0$ Hz, H-3, H-5), 6.33 (1H, d, $J = 16.0$ Hz, H-8). FABMS m/z : 164.1 $[M + H]^+$.

***trans-N-p*-Coumaroyltyramine (11)** – Amorphous powder. $^1\text{H-NMR}$ (500 MHz, CD_3OD): δ 7.33 (1H, d, $J = 15.5$ Hz, H-7), 7.02 (1H, d, $J = 1.5$ Hz, H-2), 7.00 (2H, d, $J = 8.5$ Hz, H-2', H-6'), 6.95 (1H, dd, $J = 8.5, 1.5$ Hz, H-6), 6.69 (1H, d, $J = 8.5$ Hz, H-5), 6.62 (2H, d, $J = 8.5$ Hz, H-3', H-5'), 6.30 (1H, d, $J = 15.5$ Hz, H-8), 3.38 (2H, t, $J = 7.5$ Hz, H-8), 2.66 (2H, t, $J = 7.5$ Hz, H-7); $^{13}\text{C-NMR}$ (125 MHz, CD_3OD): δ 167.2 (C-9), 155.6 (C-4'), 147.5 (C-4), 145.5 (C-3), 141.0 (C-7), 131.0 (C-1), 130.7 (C-2', C-6'), 127.1 (C-1), 121.0 (C-6), 117.3 (C-8), 116.3 (C-5), 116.0 (C-3', C-5'), 114.1 (C-2), 42.0 (C-8'), 34.0 (C-7'). FABMS m/z : 284.2 $[M + H]^+$.

***cis-N*-Coumaroyltyramine (12)** – Amorphous powder. $^1\text{H-NMR}$ (500 MHz, CD_3OD): δ 7.26 (2H, d, $J = 8.5$ Hz, H-2', H-6'), 6.91 (2H, d, $J = 8.5$ Hz, H-2, H-6), 6.65 (2H, d, $J = 8.5$ Hz, H-3', H-5'), 6.62 (2H, d, $J = 8.5$ Hz, H-3, H-5), 6.51 (1H, d, $J = 12.5$ Hz, H-8), 5.69 (1H, d, $J = 12.5$ Hz, H-7), 3.29 (2H, t, $J = 7.5$ Hz, H-8'), 2.59 (2H, t, $J = 7.5$ Hz, H-7'); $^{13}\text{C-NMR}$ (125 MHz, CD_3OD): δ 170.4 (C-9), 159.4 (C-4), 156.9 (C-4'), 138.1 (C-7), 132.3 (C-2', C-6'), 131.2 (C-1'), 130.7 (C-2, C-6), 127.9 (C-1), 121.4 (C-8), 116.2 (C-3, C-5), 116.0 (C-3', C-5'), 42.3 (C-8'), 35.5 (C-7'). FABMS m/z : 284.2 $[M + H]^+$.

Tryptophan (13) – Amorphous powder. $^1\text{H-NMR}$ (500 MHz, $\text{DMSO-}d_6$): δ 10.95 (1H, s, H-NH), 7.55 (1H, d, $J = 7.5$ Hz, H-4), 7.34 (1H, d, $J = 7.5$ Hz, H-7), 7.22 (1H, s, H-2), 7.05 (1H, t, $J = 7.5$ Hz, H-5), 6.96 (1H, t, $J = 7.5$ Hz, H-6), 3.53 (1H, m, H-12), 3.33 (1H, m, H-10a), 3.03 (1H, m, H-10b); $^{13}\text{C-NMR}$ (125 MHz, $\text{DMSO-}d_6$): δ 171.0 (C-12), 137.1 (C-8), 127.9 (C-9), 124.8 (C-2), 121.6 (C-4), 119.1 (C-5), 118.9 (C-6), 112.0 (C-7), 110.3 (C-3), 55.5 (C-11), 27.9 (C-10).

Thymidine (14) – Amorphous powder. $^1\text{H-NMR}$ (500 MHz, CD_3OD): δ 7.81 (1H, s, H-6), 6.28 (1H, t, $J = 7.0$ Hz, H-1'), 4.40 (1H, m, H-3'), 3.90 (1H, dd, $J = 6.5, 3.5$ Hz, H-4'), 3.79 (1H, dd, $J = 12.0, 3.5$ Hz, H-5'a), 3.72 (1H, dd, $J = 12.0, 3.5$ Hz, H-5'b), 2.20 (2H, m, H-2'), 1.88 (3H, s, H-7).

Adenosine (15) – Amorphous powder. $^1\text{H-NMR}$ (500 MHz, CD_3OD): δ 8.30 (1H, s, H-2), 8.18 (1H, s, H-8), 5.96 (1H, d, $J = 6.0$ Hz, H-1'), 4.74 (1H, t, $J = 6.0$ Hz, H-2'), 4.33 (1H, dd, $J = 6.0, 2.0$ Hz, H-3'), 4.17 (1H, m, H-4'), 3.88 (1H, dd, $J = 12.5, 2.5$ Hz, H-5'a), 3.74 (1H, dd,

$J = 12.5, 3.0$ Hz, H-5'b)

Deoxyadenosine (16) – Amorphous powder. $^1\text{H-NMR}$ (500 MHz, CD_3OD): δ 8.32 (1H, s, H-2), 8.18 (1H, s, H-8), 6.43 (1H, d, $J = 7.0$ Hz, H-1'), 4.58 (1H, m, H-3'), 4.07 (1H, m, H-4'), 3.84 (1H, dd, $J = 12.5, 2.5$ Hz, H-5'a), 3.74 (1H, dd, $J = 12.5, 3.0$ Hz, H-5'b), 2.80 (1H, m, H-2'a), 2.41 (1H, m, H-2'b)

Result and Discussion

Column chromatographic separation of the 80% MeOH extract from the leaves of *H. longipes* led to the isolation of known compounds **2** - **16**, which were identified as methyl 10-hydroxy-8*E*,12*Z*-octadecadienoate (**2**),⁷ methyl coriolate (**3**),⁸ *trans*-phytol (**4**),⁹ phytene-1,2-diol (**5**),¹⁰ phyton (**6**),¹¹ (3*S*,5*R*,6*S*,7*E*,9*R*)-7-megastigmene-3,6,9-triol (**7**),¹² (3*S*,5*R*,6*S*,9*R*)-3,6,9-trihydroxymegastigman-7-ene (**8**),¹³ shikimic acid (**9**),¹⁴ *p*-coumaramide (**10**),¹⁵ *trans-N-p*-coumaroyltyramine (**11**),¹⁶ *cis-N*-coumaroyltyramine (**12**),¹⁶ tryptophan (**13**),¹⁷ thymidine (**14**),¹⁷ adenosine (**15**),¹⁷ and deoxyadenosine (**16**)¹⁷ by comparing the spectroscopic data. All compounds were isolated for the first time from this plant source. The following describes the structure elucidation of compound **1**, which was synthesized¹⁸ but was not yet isolated from natural source. 269.1733 $[M + \text{Na}]^+$; (calcd for $\text{C}_{13}\text{H}_{26}\text{O}_4 \text{Na}$, 269.1729).

Compound **1** was obtained as a colorless oil and had a molecular formula of $\text{C}_{13}\text{H}_{26}\text{O}_4$, as determined from the ion peak $[M + \text{Na}]^+$ at m/z 269.1733 $[M + \text{Na}]^+$; (calcd for $\text{C}_{13}\text{H}_{26}\text{O}_4 \text{Na}$, 269.1729) in positive ion HRFABMS. The IR spectrum indicated that **1** possessed C-H bond (2951 cm^{-1}) and carbonyl (1723 cm^{-1}) groups. The ^1H NMR spectrum showed an oxygenated methine [δ_{H} 4.34 (1H, t, $J = 5.5$ Hz, H-10)], three methoxy groups [δ_{H} 3.66 (3H, s, 1-OCH₃), 3.30 (6H, s, 10-OCH₃)], a methylene adjacent to carbonyl group [δ_{H} 2.29 (2H, t, $J = 7.5$ Hz, H-2)], and seven methylenes [δ_{H} 1.61 (2H, m, H-9), 1.59 (2H, m, H-3), 1.30-1.34 (10H, m, H-4 to H-8)]. The ^{13}C NMR spectrum contained 13 signals, including a carboxylic carbon [δ_{C} 174.5 (C-1)], an acetal carbon [δ_{C} 104.8 (C-10)], three methoxy carbons [δ_{C} 52.8 ($\times 2$) (10-OCH₃), 51.6 (1-OCH₃)], and eight methylene carbons [δ_{C} 34.3 (C-2), 32.7 (C-9), 29.5 (C-7), 29.4 (C-4), 29.2 (C-6), 29.1 (C-5), 25.1 (C-8), and 24.7 (C-3)]. This spectroscopic data were very similar to those of methyl 8,8-dimethoxyoctanoate¹⁹ except that the presence of additional two methylene groups [δ_{H} 1.30-1.34; δ_{C} 29.2, 29.5]. The HMBC cross-peaks of 1-OCH₃/C-1 and 10-OCH₃/C-10 confirmed the location of three methoxy groups. Analyses of ^1H - ^1H COSY, HMQC and HMBC spectra corroborated

the gross structure of **1**, which was elucidated as methyl 10,10-dimethoxydecanoate. Compound **1** was previously reported as a synthetic¹⁸ without NMR assignment. We isolated compound **1** from natural source and performed full NMR assignment of **1** for the first time. But we suggest that compound **1** could be an artifact because MeOH was used as solvent during purification.

Acknowledgments

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2012R1A5A2A 28671860). We are thankful to the Korea Basic Science Institute (KBSI) for the measurements of NMR and MS spectra.

References

- (1) Cho, J. Y.; Heo, B. G.; Yang, S. Y. *Korean J. Org. Agric.* **2005**, *13*, 389-400.
- (2) Han, H. Y.; Kim, Y. B.; Chang, K. J.; Park, C. H.; Lee, K. C. *Korean J. Plant Res.* **2000**, *13*, 62.
- (3) Mimaki, Y.; Kanmoto, T.; Kuroda, M.; Sashida, Y.; Nishino, A.; Satomi, Y.; Nishino, H. *Chem. Pharm. Bull.* **1995**, *43*, 1190-1196.
- (4) Mimaki, Y.; Kanmoto, T.; Kuroda, M.; Sashida, Y.; Satomi, Y.; Nishino, A.; Nishino, H. *Phytochemistry* **1996**, *42*, 1065-1070.
- (5) Kim, C. S.; Kim, S. Y.; Moon, E.; Lee, M. K.; Lee, K. R. *Bioorg. Med. Chem. Lett.* **2013**, *23*, 1771-1775.
- (6) Kim, C. S.; Kwon, O.W.; Kim, S.Y.; Lee, K.R. *J. Braz. Chem. Soc.* **2014**, *25*, 907-912.
- (7) Koshino, H.; Togiya, S.; Yoshihara, T.; Sakamura, S. *Tetrahedron Lett.* **1987**, *28*, 73-76.
- (8) Nor bin Omar, M.; Nor, N. N. M.; Moynihan, H.; Hamilton, R. *Biotechnol.* **2007**, *6*, 283-287.
- (9) Kim, K. H.; Lee, K. H.; Choi, S. U.; Kim, Y. H.; Lee, K. R. *Arch. Pharm. Res.* **2008**, *31*, 983-988.
- (10) Woo, K. W.; Lee, K. R. *Nat. Prod. Sci.* **2013**, *19*, 221-226.
- (11) Odinokov, V. N.; Mallyabaeva, M. I.; Spivak, Y. Yu.; Emel'yanova, G. A.; Dzhemilev, U. M. *Dokl. Chem.* **2001**, *380*, 255-257.
- (12) Kawakami, S.; Matsunami, K.; Otsuka, H.; Shinzato, T.; Takeda, Y. *Phytochemistry* **2011**, *72*, 147-153.
- (13) Yu, Q.; Otsuka, H.; Hirata, E.; Shinzato, T.; Taketa, Y. *Chem. Pharm. Bull.* **2002**, *50*, 640-644.
- (14) Kwon, J. H.; Kim, J. H.; Choi, S. E.; Park, K. H.; Lee, M. W. *Arch. Pharm. Res.* **2010**, *33*, 2011-2016.
- (15) Nishioka, T.; Watanabe, J.; Kawabata, J.; Niki, R. *Biosci. Biotech. Biochem.* **1997**, *61*, 1138-1141.
- (16) Kim, D. K.; Lim, J. P.; Kim, J. W.; Park, H. W.; Eun, J. S. *Arch. Pharm. Res.* **2005**, *28*, 39-43.
- (17) Pretsch, E.; Bühlmann, P.; Affolter, C. *Structure Determination of Organic Compounds*; Springer: Berlin, 2000; pp 238-239.
- (18) Cardinale, G.; Laan, J. A. M.; Ward, J. P. *Tetrahedron* **1985**, *41*, 2899-2902.
- (19) Ji, S. J.; Horiuchi, C. A. *Bull. Chem. Soc. Jpn.* **2000**, *73*, 1645-1652.

Received May 2, 2014
 Revised June 3, 2014
 Accepted June 6, 2014